Trials / Withdrawn
WithdrawnNCT04355676
Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Karyopharm Therapeutics Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selinexor | 20 mg selinexor oral tablet. |
Timeline
- Start date
- 2020-04-30
- Primary completion
- 2020-08-30
- Completion
- 2020-08-30
- First posted
- 2020-04-21
- Last updated
- 2023-01-20
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04355676. Inclusion in this directory is not an endorsement.